Zacks: Brokerages Expect Humacyte, Inc. (NASDAQ:HUMA) Will Post Quarterly Sales of $270,000.00

Brokerages expect Humacyte, Inc. (NASDAQ:HUMAGet Rating) to announce $270,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Humacyte’s earnings, with estimates ranging from $130,000.00 to $400,000.00. The company is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Humacyte will report full-year sales of $1.08 million for the current fiscal year, with estimates ranging from $550,000.00 to $1.60 million. For the next financial year, analysts anticipate that the firm will post sales of $15.95 million, with estimates ranging from $2.05 million to $29.85 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Humacyte.

Humacyte (NASDAQ:HUMAGet Rating) last announced its quarterly earnings results on Tuesday, March 29th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The firm had revenue of $0.18 million during the quarter, compared to analysts’ expectations of $0.26 million.

Several equities analysts have issued reports on HUMA shares. Zacks Investment Research lowered Humacyte from a “buy” rating to a “hold” rating in a research note on Saturday, April 2nd. Piper Sandler cut their target price on Humacyte from $17.00 to $10.00 in a research note on Tuesday, March 29th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Humacyte presently has an average rating of “Buy” and an average price target of $13.65.

A number of hedge funds and other institutional investors have recently modified their holdings of HUMA. Penserra Capital Management LLC acquired a new stake in Humacyte in the fourth quarter worth about $25,000. Citigroup Inc. acquired a new stake in Humacyte in the third quarter worth about $47,000. Dixon Hughes Goodman Wealth Advisors LLC acquired a new stake in Humacyte in the first quarter worth about $48,000. Bank of America Corp DE lifted its holdings in shares of Humacyte by 96.7% during the fourth quarter. Bank of America Corp DE now owns 6,887 shares of the company’s stock worth $51,000 after purchasing an additional 3,385 shares during the period. Finally, Teacher Retirement System of Texas acquired a new stake in shares of Humacyte during the fourth quarter worth about $73,000. 9.25% of the stock is owned by institutional investors and hedge funds.

HUMA opened at $7.13 on Friday. The business’s 50-day moving average is $6.64 and its two-hundred day moving average is $7.53. Humacyte has a 1 year low of $4.37 and a 1 year high of $17.45. The company has a current ratio of 20.75, a quick ratio of 20.75 and a debt-to-equity ratio of 0.40.

About Humacyte (Get Rating)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).

Featured Stories

Get a free copy of the Zacks research report on Humacyte (HUMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humacyte (NASDAQ:HUMA)

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.